Sinco Pharmaceuticals Holdings Limited

HKEX:6833.HK

0.184 (HKD) • At close November 5, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) HKD.

2024 Q22023 Q42023 Q22022 Q42022 Q22021 Q42021 Q22020 Q42020 Q22019 Q42019 Q22018 Q42018 Q22017 Q42017 Q22016 Q42016 Q22015 Q42015 Q22014 Q42014 Q22013 Q4
Revenue 1,526.8511,449.9371,090.1261,141.5791,129.9261,177.011847.0441,413.497636.306640.968535.441379.063573.894392.355414.368289.521569.373487.39608.681535.249414.83237.52
Cost of Revenue 1,353.6391,279.203937.581,027.909937.728969.588689.5171,248.25527.727512.048444.514385.546464.261350.151388.252268.007486.319417.588525.976468.315351.994205.077
Gross Profit 173.212170.734152.546113.67192.198207.423157.527165.247108.579128.9290.927-6.483109.63342.20426.11621.51483.05469.80282.70566.93462.83632.443
Gross Profit Ratio 0.1130.1180.140.10.170.1760.1860.1170.1710.2010.17-0.0170.1910.1080.0630.0740.1460.1430.1360.1250.1510.137
Reseach & Development Expenses 13.46.7911.511.27026.1600.3690.4431.1980.3871.3970.6770.8981.0982.7462.3431.8311.1970.8210.9040
General & Administrative Expenses 61.18765.4342.51743.25737.32847.57517.42619.97420.14524.1721.00828.30727.1928.13629.1227.24335.17626.81913.70510.4537.0674.38
Selling & Marketing Expenses 36.46846.61247.10149.24967.76770.50134.87428.50761.32970.06744.469150.275118.30184.80511.1149.412.063.1242.5853.9982.7941.698
SG&A 101.887114.14692.67493.398111.246120.5551.84650.38379.65590.56671.101179.533145.491112.94140.23436.65337.23629.94316.2914.4519.8616.078
Other Expenses 0000000000000000000-0.109-0.223-0.223
Operating Expenses 115.287120.937106.1590.45104.735123.36954.06255.19577.7698.1759.007200.215140.759177.38955.27733.18139.09938.13221.02217.77313.3615.855
Operating Income 57.92549.79756.27220.27280.95286.873105.681114.86428.92438.85619.324-180.042-36.969-70.737-14.118-15.13945.81839.85966.41552.48352.97522.319
Operating Income Ratio 0.0380.0340.0520.0180.0720.0740.1250.0810.0450.0610.036-0.475-0.064-0.18-0.034-0.0520.080.0820.1090.0980.1280.094
Total Other Income Expenses Net 10.0697.315-13.5030.452-2.384-11.17-13.997-9.0751.242-17.6912.466-40.6-14.404-88.414-21.5990.289-5.402-11.063-8.573-5.476-6.171.134
Income Before Tax 67.99457.11242.76920.72478.56875.70391.684105.78930.16621.16521.79-220.642-51.373-159.151-35.717-14.8540.41628.79657.84247.00746.80523.453
Income Before Tax Ratio 0.0450.0390.0390.0180.070.0640.1080.0750.0470.0330.041-0.582-0.09-0.406-0.086-0.0510.0710.0590.0950.0880.1130.099
Income Tax Expense 44.12434.35523.17413.18516.64515.90116.40320.1042.28612.8216.58411.2362.6364.7754.1962.6419.878.0549.1436.2447.4393.421
Net Income 23.8722.75719.5957.53961.92359.80275.28185.68532.4528.34515.207-231.878-48.736-154.376-31.52-11.69531.06220.91548.69935.17134.19620.032
Net Income Ratio 0.0160.0160.0180.0070.0550.0510.0890.0610.0510.0130.028-0.612-0.085-0.393-0.076-0.040.0550.0430.080.0660.0820.084
EPS 0.0120.0110.010.0040.0310.0340.0450.0510.0190.0050.009-0.14-0.029-0.096-0.02-0.0070.0210.0170.0410.0290.0290.017
EPS Diluted 0.0120.0110.010.0040.0310.0340.0450.0510.0190.0050.009-0.14-0.029-0.096-0.02-0.0070.0210.0170.0410.0290.0290.017
EBITDA 78.61165.9861.36224.68684.32589.546108.145118.433.64643.47524.032-174.943-31.705-63.011-6.595-9.77151.04845.05171.45253.69253.64422.789
EBITDA Ratio 0.0510.0460.0560.0220.0750.0760.1280.0840.0530.0680.045-0.462-0.055-0.161-0.016-0.0340.090.0920.1170.10.1290.096